Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain.
The pharmacokinetic properties of dezocine were examined in 15 patients with acute or chronic pain. In 3 groups of 5 patients each, serum levels were determined at various intervals after single intravenous doses of 5, 10, and 20 mg. After these single doses, dezocine was very rapidly distributed (mean t1/2 alpha less than 2 minutes), and then rather rapidly eliminated (mean t1/2 beta about 4 hours); the apparent volume of distribution was large (mean Vz beta about 6 L/kg) as was the total clearance (mean CL about 1.5 L/h/kg). In 2 groups of 5 patients each, serum levels were determined after the first and third of 3 intravenous doses of 5 or 20 mg given at 3-hour intervals. The pharmacokinetic parameters after these multiple doses were consistent with those after the single doses. Although some observations were suggestive, there was no unequivocal evidence that the pharmacokinetics were dose-related. In 7 serum samples containing dezocine at concentrations ranging from 12.8 to 522 ng/mL, the mean (+/- SE) proportion of dezocine bound to protein was 91.6 +/- 0.8%.
Wilson
J M
JM
Department of Pharmacy and Clinical Pharmacy, University of Massachusetts Medical Center, Worcester, USA.
Cohen
R I
RI
Kezer
E A
EA
Schange
S J
SJ
Smith
E R
ER
D000208:Acute Disease; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002908:Chronic Disease; D003516:Cycloparaffins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D010146:Pain / Q000188:drug therapy / Q000378:metabolism*; D013764:Tetrahydronaphthalenes
D000701:Analgesics, Opioid; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003516:Cycloparaffins; D013764:Tetrahydronaphthalenes; C010827:dezocine